Skip to content

To explore the anesthetic effect and safety of low-dose remifentanil combined with remimazolam tosilate in painless intestinal polyp resection

To explore the anesthetic effect and safety of low-dose remifentanil combined with remimazolam tosilate in painless intestinal polyp resection

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2300075085
Enrollment
Unknown
Registered
2023-08-24
Start date
2023-09-01
Completion date
Unknown
Last updated
2023-08-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Multiple intestinal polyps

Interventions

Group R0 (0.5ug/kg.h):Remazolam (0.5 mg/kg.h) was injected continuously during the operation, and remifentanil was injected with 0.5ug/kg.h combined pump
Group R1(1ug/kg.h):Remazolam (0.5 mg/kg.h) was injected continuously during the operation, and remifentanil was injected with 1ug/kg.h combined pump
Group R2(1.5ug/kg.h):Remazolam (0.5 mg/kg.h) was injected continuously during the operation, and remifentanil was injected with 1.5ug/kg.h combined pump
Group R3(2ug/kg.h):Remazolam (0.5 mg/kg.h) was injected continuously during the operation, and remifentanil was injected with2ug/kg.h combined pump

Sponsors

Liaocheng People’s Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
40 Years to 80 Years

Inclusion criteria

Inclusion criteria: ?Age: 40 ~ 80 years old. ?ASA grades ? to ?. ? No sedation-related drugs were used within 1 month before enrollment. ? Understand the study content, the patient or family members have signed the informed consent.

Exclusion criteria

Exclusion criteria: ? Complicated with malignant tumor, coagulation function or liver and kidney dysfunction. ? There is severe respiratory insufficiency. ? Complicated with serious heart and cerebrovascular diseases. Allergy to the narcotic drugs involved in the study. ? Excessive obesity (BMI above 35kg/m2). ? Poor cooperation, combined with serious mental illness or cognitive dysfunction.

Design outcomes

Primary

MeasureTime frame
Blood oxygen saturation;Mean arterial pressure;Heart rate;bradycardia;

Secondary

MeasureTime frame
Operation time;recovery time;PACU residence time;orientation recovery time;Record the dose and number of pressors required during the operation;The incidence of somatokinetic reaction;respiratory depression;hypotension;hiccup;postoperative dizziness, nausea and vomiting;lethargy;abdominal pain and distension;

Countries

China

Contacts

Public ContactXiangrong Du

Department of Anesthesiology, Liaocheng People’s Hospital, Liaocheng City, PR China,

1287564941@qq.com+86 182 6350 3866

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026